Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

OpGen, Inc. OPGN OTC

Other OTC • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
65/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$0.67
-97.2%

OpGen, Inc. (OPGN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $23.91. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is OPGN = $1 (-97.2% upside).

Financials: revenue is $5M, +14.6%/yr average growth. Net income is $12M, growing at +47.3%/yr. Net profit margin is 230.8% (strong). Gross margin is 99.4% (+65.5 pp trend).

Balance sheet: total debt is $2M against $7M equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 4.18 (strong liquidity). Debt-to-assets is 21.4%. Total assets: $10M.

Analyst outlook: 2 / 3 analysts rate OPGN as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 90/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 37/100 (Fail), Income 100/100 (Pass).

$0.67
▼ 97.2% Downside
Average Price Target
The 12-month price target for OpGen, Inc. is $0.67.

OPGN SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 37/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OPGN

~
VALUE Partial
50/100
OPGN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $1, implying -95.8% from the current price $24. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
OPGN: +14.6%/yr revenue is, +47.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
OPGN: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet OPGN: Debt-to-Equity (D/E) ratio 0.29 (conservative), Current ratio is 4.18 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
OPGN: Gross margin is 99.4% (+65.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
37/100
Analyst outlook: 2 / 3 analysts rate OPGN as buy (67%). Analyst consensus target is $1 (-95.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
100/100
OPGN: Net profit margin is 230.8%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0001-34
Volume1.28K
Avg Volume (30D)5.58K
Market Cap$242.67M
Beta (1Y)-1.93
Share Statistics
EPS (TTM)2.44
Shares Outstanding$4.66M
IPO Date2015-05-05
Employees85
CEOChristian-Laurent Benoit Bonte
Financial Highlights & Ratios
Revenue (TTM)$5.2M
Gross Profit$5.16M
EBITDA$12.35M
Net Income$11.99M
Operating Income$324.72K
Total Cash$1.31M
Total Debt$2.11M
Net Debt$801.24K
Total Assets$9.86M
Price / Earnings (P/E)9.8
Price / Sales (P/S)46.7
Analyst Forecast
1Y Price Target$0.67
Target High$0.67
Target Low$0.67
Upside-97.2%
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 33% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS68373L5057

Price Chart

Track all markets on TradingView
OPGN
OpGen, Inc. ↗  ·  Other OTC
Healthcare • Medical - Diagnostics & Research
0.00 52WK RANGE 34.00

People Also View

NPCE
NPCE
NeuroPace, Inc.
$15.35
+3.16%
 SGHT
SGHT
Sight Sciences, Inc.
$3.82
+3.52%
 VAPO
VAPO
Vapotherm, Inc.
$2.17
-0.46%
 MOVE
MOVE
Movano Inc.
$16.02
+20.54%
 IINN
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$0.48
-6.50%
 NURO
NURO
NeuroMetrix, Inc.
$4.58
+5.05%
 VVOS
VVOS
Vivos Therapeutics, Inc.
$1.35
+10.66%
 TLIS
TLIS
Talis Biomedical Corporation
$2.84
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message